One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Progyny now clears that threshold, with a jump from 75 to 87 Friday.
This exclusive rating from Investor's Business Daily tracks price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an RS Rating north of 80 as they launch their biggest price moves.
Risk Management In The Stock Market: How Much Money To Invest Now
While the stock is not near an ideal buy zone right now, see if it goes on to form and break out of a proper base.
Progyny saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 5% to 31%. Revenue rose from 2% to 11%.
The company holds the No. 3 rank among its peers in the Medical-Services industry group. Option Care Health is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
